Intervals Between PCV13 and PPSV23 Vaccines: Recommendations of the Advisory Committee on Immunization Practices (ACIP).

Abstract

Two pneumococcal vaccines are currently licensed for use in the United States: the 13-valent pneumococcal conjugate vaccine (PCV13 [Prevnar 13, Wyeth Pharmaceuticals, Inc., a subsidiary of Pfizer Inc.]) and the 23-valent pneumococcal polysaccharide vaccine (PPSV23 [Pneumovax 23, Merck and Co., Inc.]). The Advisory Committee on Immunization Practices (ACIP) currently recommends that a dose of PCV13 be followed by a dose of PPSV23 in all adults aged ≥65 years who have not previously received pneumococcal vaccine and in persons aged ≥2 years who are at high risk for pneumococcal disease because of underlying medical conditions (Table) (1-4). The recommended intervals between PCV13 and PPSV23 given in series differ by age and risk group and the order in which the two vaccines are given (1-4).

• Authors: Miwako Kobayashi, Nancy M Bennett, Ryan Gierke, Olivia Almendares, Matthew R Moore, Cynthia G Whitney, Tamara Pilishvili
• Journal: MMWR. Morbidity and mortality weekly report (MMWR Morb Mortal Wkly Rep) Vol. 64 Issue 34 Pg. 944-7 (Sep 04 2015) ISSN: 1545-861X [Electronic] United States
• PMID: 26334788 (Publication Type: Journal Article)

Chemical References

• 13-valent pneumococcal vaccine
• 23-valent pneumococcal capsular polysaccharide vaccine
• Pneumococcal Vaccines
• Vaccines, Conjugate

Topics

• Adolescent
• Adult
• Advisory Committees
• Age Factors
• Aged
• Child
• Child, Preschool
• Humans
• Immunization Schedule
• Middle Aged
• Pneumococcal Infections (prevention & control)
• Pneumococcal Vaccines (administration & dosage)
• Practice Guidelines as Topic
• Risk Factors
• United States
• Vaccines, Conjugate (administration & dosage)
• Young Adult